FX-322 in Sensorineural Hearing Loss
A Phase 1/2 Randomized, Double-blind, Placebo-controlled Single Dose Study at Two Dose Levels of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss
Sponsor: Frequency Therapeutics
Listed as NCT03616223, this PHASE1/PHASE2 trial focuses on Sensorineural Hearing Loss and remains completed. Sponsored by Frequency Therapeutics, it has been updated 13 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 8 earlier versions
-
Apr 2022 — Sep 2022 [monthly]
Completed PHASE1_PHASE2
-
Apr 2021 — Apr 2022 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Completed PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Sep 2020 — Oct 2020 [monthly]
Completed PHASE1_PHASE2
-
May 2019 — Sep 2020 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Nov 2018 — May 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Nov 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jul 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Frequency Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .